Contenido principal
Ir al contenido principal
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Selector de idioma
Es
En
Español
English
Cerrar
Nuestros investigadores
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Menú de navegación
No hay
Navegación secundaria
disponible para el sitio actual.
Nuestros investigadores
Cerrar
Ruta de navegación
Estás en:
Investigacion
Nuestros investigadores
Curriculum de nuestros investigadores
Curriculum de nuestros investigadores - Investigacion
Detalle Profesor
Nuestros investigadores
Esther Pena Carbó
Publicaciones
Revistas (6)
Docencia
Revistas
Autores:
Duell, J.; Jurczak, W.; Liberati, A. M.; et al.
Título:
EL-MIND: safety and efficacy of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma on treatment for at least 2 years
Revista:
CLINICAL LYMPHOMA MYELOMA AND LEUKEMIA
ISSN:
2152-2650
Año:
2022
Vol.:
22
N°:
Supl. 2
Págs.:
S375
Autores:
Duell, J.; Jurczak, W.; Liberati, A. M.; et al.
Título:
L-Mind: a safety and efficacy analysis of tafasitamab in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving treatment for at least 2 years
Revista:
BLOOD
ISSN:
0006-4971
Año:
2022
Vol.:
140
N°:
Supl. 1
Págs.:
6596 - 6598
Autores:
López Díaz de Cerio, A
; Garcia-Munoz, R.;
Pena, E
; et al.
Título:
Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression
Revista:
BRITISH JOURNAL OF HAEMATOLOGY
ISSN:
0007-1048
Año:
2020
Vol.:
189
N°:
6
Págs.:
1064 - 1073
Resumen
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised thatex vivoexpanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy. This open, prospective, phase II, single-arm study assessed safety and efficacy ofex vivoexpanded LAK cells in 20 FL-remission patients following rituximab maintenance. Mononuclear cells were obtained in odd rituximab cycles and stimulated with interleukin 2 (IL-2) for 8 weeks, after which >5 x 10(8)LAK cells were injected. Patients were followed-up for 5 years. At the end of maintenance, peripheral blood cells phenotype had not changed markedly. Natural killer, LAK and ADCC activities of mononuclear cells increased significantly after recombinant human IL-2 (rhIL-2) stimulation in all cycles. Rituximab significantly enhanced cytotoxic activity. No patients discontinued treatment. There were no treatment-related serious adverse events. Three patients had progressed by the end of follow-up. After a median (interquartile range) follow-up of 59.4 (43.8-70.9) months, 85% of patients remained progression free. No deaths occurred. Quality-of-life improved throughout the study. Post-induction LAK cells with rituximab seem safe in the long term. Larger studies are warranted to confirm efficacy.
Autores:
Pena, E
; Munoz, R. G.;
López Díaz de Cerio, A
; et al.
Título:
La infusión de linfocitos efectores autólogos en combinación con rituximab de mantenimiento es segura y eficaz. Resultados del ensayo clínico fase ii lfnk
Revista:
HAEMATOLOGICA
ISSN:
0390-6078
Año:
2019
Vol.:
104
Págs.:
3 - 4
Autores:
García-Muñoz, R.;
López Díaz de Cerio, A
; Feliu, J.; et al.
Título:
Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity
Revista:
IMMUNOLOGIC RESEARCH
ISSN:
0257-277X
Año:
2016
Vol.:
64
N°:
2
Págs.:
548 - 57
Resumen
Follicular lymphoma (FL) is a disease of paradoxes-incurable but with a long natural history. We hypothesized that a combination of lymphokine-activated killer (LAK) cells and monoclonal antibodies might provide a robust synergistic treatment and tested this hypothesis in a phase II clinical trial (NCT01329354). In this trial, in addition to R-CHOP, we alternated the administration of only rituximab with rituximab and autologous LAK cells that were expanded ex vivo. Our objective was to determine the in vitro capability of LAK cells generated from FL patients to produce cytotoxicity against tumor cell lines and to determine rituximab- and obinutuzumab-induced cytotoxicity via antibody-dependent cellular cytotoxicity (ADCC) activity. We analyzed the LAK cell-induced cytotoxicity and rituximab (R)- and obinutuzumab (GA101)-induced ADCC activity. We show that LAK cells generated from FL patients induce cytotoxicity against tumor cell lines. R and GA101 enhance cytolysis through ADCC activity of LAK cells. Impaired LAK cell cytotoxicity and ADCC activity were detected in 50 % of patients. Percentage of NK cells in LAK infusions were correlated with the R- and GA101-induced ADCC. Our results indicate that the combination of R or GA101 and LAK cells should be an option as frontline maintenance therapy in patients with FL.
Autores:
Robles, Eloy Francisco
;
Mena , María
; Barrio, L.; et al.
Título:
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics
Revista:
NATURE COMMUNICATIONS
ISSN:
2041-1723
Año:
2016
Vol.:
7
Págs.:
11889
Resumen
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-¿B and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas
Curso 2021 - 2022
- Hematología (F.Medicina).
Universidad de Navarra - Facultad de Medicina .
Curso 2020 - 2021
- Hematología (F.Medicina).
Universidad de Navarra - Facultad de Medicina .
Oculto